Bavarian Nordic A/S Stock
€20.07
Your prediction
Bavarian Nordic A/S Stock
Bavarian Nordic (symbol: BAVA) is a biotechnology company that specializes in developing innovative vaccines for serious diseases such as cancer and infectious diseases like Ebola and COVID-19. The company has a broad portfolio of vaccines that are under development and has collaboration agreements with various pharmaceutical companies and government agencies. Bavarian Nordic's flagship product is its cancer vaccine known as PROSTVAC, which is currently undergoing clinical trials for the treatment of prostate cancer. The company is listed on the NASDAQ Copenhagen stock exchange and has a market capitalization of approximately $925 million as of May 2021.
Pros and Cons of Bavarian Nordic A/S in the next few years
Pros
Cons
Performance of Bavarian Nordic A/S vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Bavarian Nordic A/S | -0.670% | -2.000% | -4.424% | -21.707% | -16.880% | -47.326% | - |
| ALK-Abelló A/S B | 1.500% | -2.341% | -2.226% | 50.496% | 25.772% | -4.900% | 133.101% |
| Beijing Tong Ren Tang Chinese Medicine Co Ltd | - | -0.926% | 0.000% | -41.848% | -23.022% | -13.008% | -36.910% |
| Laboratorios Farmaceuticos | 0.000% | -1.946% | 1.066% | 95.347% | 33.113% | 74.837% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon initial examination of the financials for the company Bavarian Nordic with the US symbol BAVA, it appears that the company has experienced some fluctuations over the past few years. A quick look into the balance sheets, cash flows, and income statements reveal a somewhat mixed picture. However, before drawing any conclusions, let's delve deeper into the specifics to evaluate the pros and cons of the company's financials.
Rising Total Assets: The total assets have been on an upward trend from DKK 8,759,064,000 in 2020 to DKK 13,180,857,000 in 2023 Q1. The increase in assets is generally a good sign of the company's growth and stability.
Increase in Cash and Cash Equivalents: From 2020 to 2023 Q1, the company's cash in hand has increased from DKK 285,487,000 to DKK 1,271,717,000. This provides the company with more financial flexibility moving forward.